Newsroom

Immunotherapy against hepatitis B
News
Who benefits from immunotherapy against hepatitis B?
Hepatitis B is a viral infection of the liver that can lead to cancer and organ failure. Antiviral therapies can suppress the infection, but a functional cure is rare. Novel immunotherapies may lead to an actual cure more often. However, it is still unclear which patients benefit most from these new therapies. Researchers at the Centre for Individualised Infection Medicine (CiiM), a joint institution of the Helmholtz Centre for Infection Research (HZI) and the Hannover Medical School (MHH), as well as the MHH and the German Center for Infection Research (DZIF), have now identified a biomarker that intends to enable predictions about the success of the therapy. The results were published in the scientific journal Gut.
25.11.2021
CiiM
Infection and immunity week
News
Joint symposium of HZI and McGill University on personalised infection medicine
The Helmholtz Centre for Infection Research (HZI) in Braunschweig and the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) at McGill University in Montréal, Canada, are organising a joint symposium on personalised infection medicine on 29 November. Three researchers from each of the two institutions will give lectures on various topics of personalised infection medicine. The keynote lecture will be given by Prof Ugur Sahin, co-founder and CEO of BioNTech SE. The symposium kicks off McGill University's “Infection and Immunity Week”, which celebrates its 200th anniversary this year. Interested scientists can register to follow the event online.
23.11.2021
HZI Campus
CiiM
HIRI
Filterplättchen
News
20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance
Ahead of the “World Antimicrobial Awareness Week” (November 18-24) 20 national and international organizations from academia, healthcare and the pharmaceutical industry appealed today to G7 governments to step up efforts to tackle the problem of growing antibiotic resistance. Their "Joint Statement on Strengthening the Antibiotic R&D Pipeline by Rewarding Innovation" stresses that only an approach involving both the public and private sectors is likely to succeed. The Helmholtz Centre for Infection Research (HZI) is a member of the Helmholtz Association of German Research Centres and the German Center for Infection Research (DZIF), which both signed the statement.
17.11.2021
HZI Campus
Aktin-Zytoskelett in Maus-Melanomzellen
News
How molecular forces regulate cell migration
Researchers from the Helmholtz Centre for Infection Research (HZI) and partners from the University of Bordeaux have established a mechanism that regulates the migration of individual cells. The study was recently published in Nature Cell Biology and discussed in an accompanying article by renowned experts.
16.11.2021
HZI Campus
Illustration von antiviralen Wirkstoffen
News
The HZI is on the leap to new antiviral agents
The Federal Agency for Disruptive Innovation (SPRIND) has announced the participants of the first SPRIND Challenge “A Quantum Leap for New Antiviral Agents”. From 45 applications from Germany and Europe, the jury selected a total of nine teams. Prof Mark Brönstrup from the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Prof Chase Beisel from the Helmholtz Institute for RNA-based Infection Research (HIRI), a joint institution of the HZI with the Julius-Maximilians-Universität Würzburg (JMU), convinced the jury with the projects they led. The HZI scientists Prof Carlos A. Guzmán and Dr Christian Sieben are involved in two other projects as cooperation partners. The teams will each receive up to 700,000 euros in the first year of the three-year competition to develop new drug candidates against viral diseases.
10.11.2021
HZI Campus
HIPS
HIRI
Gruppenbild
News
BMBF FUNDING "GO-BIO": HIRI RECEIVES UP TO 733,000 EUROS
The Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) is supporting the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg - an institution of the Helmholtz Centre for Infection Research Braunschweig in cooperation with the Julius-Maximilians-University - with up to 733,000 euros. The grant is awarded to Daphne Collias, a post-doc in Chase Beisel’s lab at HIRI, to take the new and award-winning LEOPARD technology a decisive step further towards commercialization. In the future, LEOPARD may help physicians and patients by providing more comprehensive diagnostic information about a patient’s health. The funding is part of the "GO-Bio initial" program from the BMBF and is granted for a period of 24 months.
03.11.2021
HIRI

HZI in the media

Seuchen aus dem KI-Labor: Kann Künstliche Intelligenz bereits Biowaffen bauen?

... beeindruckendes Ergebnis“, sagt Jakob Wirbel vom Helmholtz-Zentrum für Infektionsforschung (HZI). „Trotzdem schlafe ich momentan noch ...

15.10.2026
|
Der Tagesspiegel
Impfung sinnvoll? Erst Erkältungen, dann Corona und Grippe – So schützen Sie sich

... Lange, Leiterin der Abteilung Epidemiologie am Helmholtz-Zentrum für Infektionsforschung in Braunschweig und Mitglied der Ständigen ...

14.10.2026
|
DIE WELT
HMN 2026: How crawling motility may be far older than previously thought

also included Japanese microbiologists and collaborators from IST Austria and HZI Braunschweig (Germany), demonstrated that actin inhibitors

14.10.2026
|
Health Medicine Network
Neue Empfehlungen der WHO zur COVID-19-Impfung

... in der Abteilung „Virale Immunologie“ am Helmholtz-Zentrum für Infektionsforschung (HZI), hat die WHO als externer ...

13.10.2026
|
DeutschesGesundheitsPortal
Metax brings genome-wide coverage into focus for sharper microbial profiling

tool called Metax, developed by researchers at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and described in the

12.10.2026
|
Bioengineer.org
New Hope for Fighting C. difficile Infections

parts of the microbiome. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University. “We

12.10.2026
|
Technology Networks
HZI erhält 724.000 Euro: Makrophagen sollen Lungenfibrose bekämpfen

... auch gezielte Forschungsmittel an das Helmholtz-Zentrum für Infektionsforschung (HZI): Die Forschungsgruppe von Prof ...

12.10.2026
|
Ad Hoc News
Fieser Magen-Darm-Erreger breitet sich immer stärker aus: Infektionen in England steigen drastisch

... nur in England vor. Laut Angaben des Helmholtz Zentrum für Infektionsforschung ist es dem Erreger ...

12.10.2026
|
Frankfurter Rundschau online
EU fördert Entwicklung von Immunzelltherapie bei Lungenfibrose

... und Belgien. Aus Deutschland sind das Helmholtz-Zentrum für Infektionsforschung (HZI), das Fraunhofer-Institut für Toxikologie und ...

12.10.2026
|
MTA Dialog
Forscher entwickeln Wirkstoff gegen Pockenviren

... weitere Versuche herstellen.

 

Auch das Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig ist beteiligt. Die ...

11.10.2026
|
t-online.de
Warum Ballaststoffe nicht bei jedem gleich wirken

... unterschiedlichen Regionen unterscheidet. Der Forscher vom Helmholtz-Zentrum für Infektionsforschung konnte in seiner Studie zeigen, ...

10.10.2026
|
rbb radioeins
Gut bacteria team up with diet to decide who rules the microbiome

Tawk, Youssef El Mouali and colleagues at the Helmholtz Centre for Infection Research, together with collaborators at the University of

09.10.2026
|
Bioengineer.org

Register now for the HZI newsletter